Literature DB >> 8549007

Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM).

M I Harris1.   

Abstract

The diagnostic criteria of the US National Diabetes Data Group and the World Health Organization have stimulated a major increase throughout the world in epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). They have established that much of NIDDM is undiagnosed, that onset of NIDDM occurs at least 7 y before its diagnosis, and that significant morbidity and premature mortality occur in subjects with undiagnosed diabetes. New studies have shown that rural or traditional-living populations are experiencing a major increase in the burden of NIDDM as they move to urban or nontraditional situations, often with 5- to 10-fold increases in NIDDM prevalence. Epidemiologic studies have documented that major risk factors for NIDDM include increasing age, greater obesity, longer duration of obesity, unfavourable body fat distribution, physical inactivity, and hyperinsulinemia. All these factors interact with unknown genetic factors to produce NIDDM. Studies have shown that genes for diabetes, as yet undetermined, are a necessary cause of NIDDM. Hyperinsulinemia exists in childhood in populations at high risk for NIDDM. Stimulated by obesity, upper body obesity, and physical inactivity, insulin resistance develops, accompanied by impaired glucose tolerance. The pressure of the NIDDM risk factors continues this process of insulin resistance/hyperinsulinemia/hyperglycemia, until glucose toxicity to the beta cell results in inability to secrete sufficient insulin, resulting in decompensated fasting hyperglycemia.

Entities:  

Mesh:

Year:  1995        PMID: 8549007

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  9 in total

1.  Mechanisms of insulin resistance in experimental hyperinsulinemic dogs.

Authors:  P D Miles; S Li; M Hart; O Romeo; J Cheng; A Cohen; K Raafat; A R Moossa; J M Olefsky
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

2.  alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population.

Authors:  Walter E Gall; Kirk Beebe; Kay A Lawton; Klaus-Peter Adam; Matthew W Mitchell; Pamela J Nakhle; John A Ryals; Michael V Milburn; Monica Nannipieri; Stefania Camastra; Andrea Natali; Ele Ferrannini
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

3.  The prevalence of type 2 diabetes and gestational diabetes mellitus in an inner city multi-ethnic population.

Authors:  R N Weijers; D J Bekedam; H Oosting
Journal:  Eur J Epidemiol       Date:  1998-10       Impact factor: 8.082

4.  Relationship between beta-cell mass and diabetes onset.

Authors:  A V Matveyenko; P C Butler
Journal:  Diabetes Obes Metab       Date:  2008-11       Impact factor: 6.577

Review 5.  Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.

Authors:  James F McLeod
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Influences on the variation in prevalence of type 2 diabetes between general practices: practice, patient or socioeconomic factors?

Authors:  David L Whitford; Simon J Griffin; A Toby Prevost
Journal:  Br J Gen Pract       Date:  2003-01       Impact factor: 5.386

7.  Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes.

Authors:  Paul Valensi
Journal:  Diabetes Metab Syndr Obes       Date:  2009-06-03       Impact factor: 3.168

Review 8.  The dynamic plasticity of insulin production in β-cells.

Authors:  Brandon B Boland; Christopher J Rhodes; Joseph S Grimsby
Journal:  Mol Metab       Date:  2017-05-04       Impact factor: 7.422

9.  Associations of Helicobacter pylori infection and peptic disease with diabetic mellitus: Results from a large population-based study.

Authors:  Saeda Haj; Gabriel Chodick; Rotem Refaeli; Sophy Goren; Varda Shalev; Khitam Muhsen
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.